LONG-TERM CLINICAL OUTCOMES WITH EVEROLIMUS-ELUTING STENTS AND SIROLIMUS-ELUTING STENTS: AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS  by Toyota, Toshiaki et al.
TCT@ACC-i2: Interventional Cardiology
A1846
JACC March 17, 2015
Volume 65, Issue 10S
lonG-term CliniCal oUtComes with everolimUs-elUtinG stents and sirolimUs-elUtinG 
stents: an Updated meta-analysis oF randomiZed Controlled trials
Poster Contributions
Poster Hall B1
Sunday, March 15, 2015, 9:45 a.m.-10:30 a.m.
Session Title: Peripheral and Vascular Biology
Abstract Category: 34. TCT@ACC-i2: Coronary Intervention: Devices
Presentation Number: 2102-312
Authors: Toshiaki Toyota, Hiroki Shiomi, Takeshi Morimoto, Takeshi Kimura, Kyoto University Graduate School of Medicine, Kyoto, Japan
background: The superiority of everolimus-eluting stents (EES) over sirolimus-eluting stents (SES) for long-term clinical outcomes has not 
been yet firmly established.
methods: We conducted a systematic review and a meta-analysis of randomized controlled trials (RCTs) comparing EES directly with SES 
using the longest available follow-up data. We searched PubMed, the Cochrane database, and ClinicalTrials.gov. for RCTs comparing 
outcomes between EES and SES.
results: We identified 13,434 randomly assigned patients from 14 RCTs. EES was associated with significantly lower risks than SES for 
definite stent thrombosis, definite/probable stent thrombosis, target-lesion revascularization, and major adverse cardiac events (pooled 
odds ratio (OR) 0.56, 95% confidence interval (CI) 0.35-0.90, P=0.02, OR 0.64, 95%CI 0.45-0.92, P=0.02, OR 0.83, 95%CI 0.70-0.98, 
P=0.03, and OR 0.86, 95%CI 0.76-0.96, P=0.01, respectively). The risks for all-cause death and myocardial infarction were similar between 
EES and SES. By the stratified analysis according to the timing after stent implantation, the favorable trend of EES relative to SES for stent 
thrombosis, target-lesion revascularization, and major adverse cardiac events was consistently observed both within and beyond 1-year. 
The lower risk of EES relative to SES for major adverse cardiac events beyond 1-year was statistically significant (OR 0.77, 95%CI 0.61-
0.96, P=0.02).
Conclusion:  In the current meta-analysis of 14 RCTs directly comparing EES with SES, EES as compared with SES was associated with 
significantly lower risk for definite stent thrombosis, definite/probable stent thrombosis, target-lesion revascularization, and major adverse 
cardiac events, suggesting that EES provided improvement in both safety and efficacy. The direction and magnitude of the effect beyond 
1-year were comparable to those observed within 1-year. 
